Innovative Technology

ITL Pharma is a privately held pharmaceutical company focused on the discovery and development of novel therapeutics within the emerging field of Free Radical Oxidative Medicine. The company's research centers on the hypothesis that aging and various chronic diseases result from the accumulation of free radical oxidative species (FROS), which damage cellular components. ITL Pharma has developed a proprietary class of diagnostic and therapeutic compounds designed to detect, capture, and neutralize these destructive free radicals. Its pipeline includes over 20 drug candidates targeting a broad range of conditions, including neurodegenerative disorders like Alzheimer's and Parkinson's, as well as inflammatory and cardiovascular diseases. Headquartered in Tennessee, the company operates its own research and development facility to advance its candidates toward clinical trials.